Source comparison
Best MK-677 Supplier Third Party Tested 2026: Comparison
Synthesis Method In-house SPPS, <10g batches Contract manufacturer, bulk synthesis Overseas bulk purchase, unknown method Small-batch SPPS allows per-batch testing and faster issue resolution. Bulk methods prioritize cost over consistency Third-Party Testing H
This comparison does not assign a generated winner or score.
- Synthesis Method
- In-house SPPS, <10g batches
- Contract manufacturer, bulk synthesis
- Overseas bulk purchase, unknown method
- Small-batch SPPS allows per-batch testing and faster issue resolution. Bulk methods prioritize cost over consistency
- Third-Party Testing
- HPLC-MS + AA analysis + endotoxin LAL, independent lab
- HPLC only, may use supplier's lab
- COA provided but testing date often months old
- Full orthogonal testing (HPLC, MS, AA, endotoxin) is non-negotiable for research-grade peptides. HPLC alone doesn't confirm structure
- COA Transparency
- Published per-batch, <72hr post-synthesis
- Generic COA, batch numbers may not match product
- Single COA reused across batches
- Real-time COA with matching batch numbers proves current purity. Reused COAs signal resale of aged stock
- Storage and Shipping
- Cold-chain with temp logging, ships <30 days post-synthesis
- Ambient shipping, no temp monitoring
- Long-term storage before shipping
- Temperature excursions during shipping cause irreversible aggregation. Cold-chain logistics are required, not optional
- Regulatory Compliance
- FDA-registered facility, DMF on file
- No facility registration, reseller only
- Overseas manufacture, no FDA oversight
- FDA registration and DMF prove direct manufacturing oversight. Resellers lack quality control authority
- Purity Consistency
- 98.5-99.2% across batches (verified 6-month span)
- 94-97% typical, higher variance
- 92-96%, significant batch-to-batch drift
- Purity variance >2% between batches undermines dose-response reproducibility. Consistency matters more than peak purity
- The comparison reveals a pattern: suppliers controlling their own synthesis deliver tighter purity ranges and more comprehensive testing. Resellers and importers introduce variability at every step. From synthesis method to storage duration to shipping conditions. For protocols requiring reproducible growth hormone signaling, that variability translates directly to confounded data.